Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vinorelbine Metronomic Plus Lapatinib in HER2+ Metastatic Breast Cancer
NCT00754702Phase 2Terminated
- Sponsor
- University Hospital of Crete
- Start
- Oct 2008
- Primary completion
- Mar 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vinorelbine and lapatinib in breast cancer, sponsored by University Hospital of Crete. Primary endpoint: Overall Response Rate. Started Oct 2008; status: terminated.
02
Drugs
vinorelbinelapatinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00754702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00754702.